Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13452405 | 0.78 | SLC6A3 (0.32) | SLC6A3CA12CA1CA9 | |
| SCHEMBL4251643 | 0.75 | MAPT (0.44) | RAPGEF4 | |
| SCHEMBL10087241 | 0.75 | RAB9A (0.42) | — | |
| Hydrochloric Acid SCHEMBL27258925 | 0.73 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL179354 | 0.73 | GABRA1 (0.46) | SLC6A3CA12CA1CA9 | |
| SCHEMBL16105792 | 0.73 | ALOX15 (0.40) | SLC6A3CA12CA1CA9RAPGEF4 | |
| SCHEMBL13452475 | 0.70 | HDAC3 (0.44) | SLC6A3RAPGEF4 | |
| SCHEMBL25485523 | 0.69 | CA12 (0.41) | SLC6A3CA12CA1CA9 | |
| SCHEMBL20993112 | 0.69 | CA12 (0.35) | SLC6A3CA12CA1CA9 | |
| SCHEMBL18465499 | 0.69 | CA12 (0.35) | SLC6A3CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-7390905-B2 | Piperidine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390905-B2 | Piperidine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390905-B2 | Piperidine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20070112029-A1 | Piperidine compound and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112029-A1 | Piperidine compound and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112029-A1 | Piperidine compound and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1693367-A1 | PIPERIDINE COMPOUND AND METHOD FOR PRODUCING SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SLC6A3 248/4885CA12 2666/4885CA1 1063/4885 |
| US-20070112029-A1 | Piperidine compound and process for preparing the same | NPSR1, TACR1, PRLHR | SLC6A3 1317/4885CA12 4471/4885CA1 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.